• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2009; 4(11): e7819.
Published online Nov 12, 2009. doi:  10.1371/journal.pone.0007819
PMCID: PMC2773002

Differential Role of Human Choline Kinase α and β Enzymes in Lipid Metabolism: Implications in Cancer Onset and Treatment

Suzannah Rutherford, Editor

Abstract

Background

The Kennedy pathway generates phosphocoline and phosphoethanolamine through its two branches. Choline Kinase (ChoK) is the first enzyme of the Kennedy branch of synthesis of phosphocholine, the major component of the plasma membrane. ChoK family of proteins is composed by ChoKα and ChoKβ isoforms, the first one with two different variants of splicing. Recently ChoKα has been implicated in the carcinogenic process, since it is over-expressed in a variety of human cancers. However, no evidence for a role of ChoKβ in carcinogenesis has been reported.

Methodology/Principal Findings

Here we compare the in vitro and in vivo properties of ChoKα1 and ChoKβ in lipid metabolism, and their potential role in carcinogenesis. Both ChoKα1 and ChoKβ showed choline and ethanolamine kinase activities when assayed in cell extracts, though with different affinity for their substrates. However, they behave differentially when overexpressed in whole cells. Whereas ChoKβ display an ethanolamine kinase role, ChoKα1 present a dual choline/ethanolamine kinase role, suggesting the involvement of each ChoK isoform in distinct biochemical pathways under in vivo conditions. In addition, while overexpression of ChoKα1 is oncogenic when overexpressed in HEK293T or MDCK cells, ChoKβ overexpression is not sufficient to induce in vitro cell transformation nor in vivo tumor growth. Furthermore, a significant upregulation of ChoKα1 mRNA levels in a panel of breast and lung cancer cell lines was found, but no changes in ChoKβ mRNA levels were observed. Finally, MN58b, a previously described potent inhibitor of ChoK with in vivo antitumoral activity, shows more than 20-fold higher efficiency towards ChoKα1 than ChoKβ.

Conclusion/Significance

This study represents the first evidence of the distinct metabolic role of ChoKα and ChoKβ isoforms, suggesting different physiological roles and implications in human carcinogenesis. These findings constitute a step forward in the design of an antitumoral strategy based on ChoK inhibition.

Introduction

Human choline kinase alpha (ChoKα) and beta (ChoKβ) are members of the choline kinase family. In mammals this family is encoded by two separate genes, CHKA and CHKB, resulting in three different proteins with a choline/ethanolamine kinase (ChoK/EtnK) domain: ChoKα1 (NP_001268), ChoKα2 (NP_997634) and ChoKβ1 (NP_005189) [1]. ChoKα1 differs from ChoKα2 in only an extra stretch of 18 amino acids, while ChoKβ differs from ChoKα1 and ChoKα2 in approximately 40%. The presence of the ChoK/EtnK domain confers the capacity to catalyze the phosphorylation of choline (Cho) to phosphocholine (PCho) [1]. This constitutes the first step in the biosynthesis pathway of phosphatidylcholine (PC) [2]. PC is the major phospholipid in eukaryotic membranes and plays a critical role in membrane structure and also in cell signalling [2]. ChoK enzymes could be implicated also in the synthesis of phosphatidylethanolamine (PE), using as substrate ethanolamine to render phosphoethanolamine (PEtn) [1], [3][5].

Previous studies suggest that ChoK acts as a dimeric protein [6], [7] and the proportion of the different homo- or hetero- dimer population has been proposed to be tissue-specific [8]. Furthermore, the combination between choline kinase isoforms results in a different level of ChoK activity in vitro under cell-free systems conditions. Thus, the α/α homodimer is the most active choline kinase form, the β/β homodimer the less active, and the α/β heterodimer has an intermediate phenotype [8].

The specific phospholipase D-driven hydrolysis of PC generates choline and signal transduction metabolites such as PA (phosphatidic acid), and its derivatives LPA (lysophosphatidic acid) and DAG (diacylglycerol), that are important in mitogenesis and cellular transformation [9][11]. Choline gets further converted by ChoK into PCho, an stable metabolite able to induce mitogenesis in murine fibroblasts [12]. In addition, several oncogenes such as RAS or RHOA increase ChoKα activity resulting in higher intracellular levels of PCho [13][16]. Magnetic resonance spectroscopy (MRS) studies have revealed abnormal phospholipid metabolism in cancer cells [17], [18]. Furthermore, high levels of PCho have been found in tumoral cells as well as in tumour samples of cancer patients compared with the normal counterparts in breast, prostate, brain and ovarian cancer [19][25]. The increase in phosphoethanolamine has been also reported in transformed cells or tumor samples using MRS, although it contributes to a much lesser extent, compared with the increase of PCho, to the phosphomonoester peak [26].

The implication of ChoKα in cell growth, proliferation, initiation and progression of cancer is well documented. ChoKα is overexpressed in some of the most common cancers, such as breast, lung, colorectal, prostate [27][30] and bladder (unpublished observations). Furthermore, it has oncogenic activity when overexpressed in human cells [15]. Increased ChoKα mRNA levels have been recently described as an independent prognostic marker in non small cell lung cancer patients [30]. Also, human breast cancer cell lines show upregulation of ChoKα but not ChoKβ, when compared with normal mammary epithelial cells [21]. In that sense, it has been recently reported that in the prostate tumor mouse model (TRAMP), using IHQ immunodetection of ChoKβ, a low level expression of ChoKβ was found in tumoral samples compared with wild type tissues [31].

The implication of members of the Rho GTPase family in cancer onset and progression has been extensively described [32][35]. Evidence that ChoK is involved in malignant transformation along with Ras and RhoA has been provided [14], [15], [36]. Moreover, the activity of ChoKα is modulated by known effectors of both Ras and RhoA [15], [29].

Pharmacological inhibition of ChoKα has been proposed as a novel antitumoral strategy [2]. A strong support to this strategy is based on the use of MN58b, a well-characterized ChoKα inhibitor, which displays a potent antiproliferative effect in several tumoral cell lines in vitro, and a strong reduction of tumor growth in nude mice xenografts [14], [37][40].

We have compared the biochemical and biological properties of ChoKα and ChoKβ, and demonstrate that besides their homology, the latter is not able to induce cell transformation in HEK293T or MDCK cells. Moreover, we suggest differential behaviour between α and β isoforms in phospholipids metabolism. Finally, the antitumoral properties of MN58b can be attributed to its specific inhibition of ChoKα. The implications of these findings are discussed.

Results

Characterization of enzymatic properties of ChoKα1 and ChoKβ isoforms

The activity of both choline kinase isoforms, ChoKα1 and ChoKβ, has been described previously in different mammalian tissues, however their choline kinase and/or ethanolamine kinase activities are not fully characterized [1], [4], [41][43]. Thus, we first carried out a comparative analysis of the in vitro kinase activity of the two human ChoKα1 and ChoKβ isoforms, regarding their ability to phosphorylate choline and ethanolamine. HEK293T cells were transfected with appropriate expression vectors carrying the human CHKA or CHKB genes or an empty vector, and tested for ChoK and EtnK activity. Expression levels achieved were checked by Western Blot (Figure 1a), and the relative enzymatic activity from cell extracts estimated. Both ChoKα1 and ChoKβ displayed choline and ethanolamine kinase activities under these experimental conditions, but the rate of conversion was apparently different (Figure 1b).

Figure 1
Characterization of choline and ethanolamine kinase activity of ChoKα1 and Chokβ1 in HEK293T cells.

We further analyze ChoK and EtnK kinetic activities for ChoKα1 and ChoKβ isoforms using the recombinant enzymes. DH5α Escherichia coli were transformed with the gene encoding for human ChoKα1 or ChoKβ and an enzymatic in vitro assay for either ChoK or EtnK activities performed. Michaelis constants (Km) for each isoform for the different substrates were obtained (Table 1). ChoKβ showed a Km for choline 2.8 times higher than ChoKα1. By contrast, the Km of ChoKβ for ethanolamine was lower than ChoKα1. These results suggest that in cell-free systems choline is a better substrate for ChoKα1 (2.85 fold) than ChoKβ, whereas ethanolamine is a better substrate for ChoKβ (5.83 fold) than ChoKα1.

Table 1
Michaelis constant (Km) of ChoKα and β isoforms for choline and ethanolamine.

ChoK isoforms are differentially regulated by Ras and Rho GTPases

Since Ras and RhoA GTPases are upstream regulators of ChoKα1 [15], [28], some of the most studied proteins of the small GTPase family including H-Ras, and the Rho-family members RhoA and Cdc42 were tested as potential upstream modulators of ChoKβ. To that end, an in vitro ChoK and EtnK activity assay was performed in HEK293T cells transfected with the constitutive active mutants of each GTPase (Fig. 2a) and either ChoKα1 and ChoKβ. As shown in Figure 2, none of the GTPases tested were able to significantly increase choline or ethanolamine kinase activity of ChoKβ. By contrast, under similar conditions, Ras and RhoA were able to induce a statistically significant change in the activation of both ChoK and EtnK activities of ChoKα1 (Fig. 2b and 2c).

Figure 2
Differential activation of choline kinase α1 and β1 isoforms by Ras and Rho GTPases.

Differential role between ChoK isoforms in cell transformation and tumorigenesis

The implication of ChoKα1 in cell transformation and human carcinogenesis has been extensively studied, and it has been shown to display oncogenic activity [15], [36]. Due to its extensive homology, we investigated if ChoKβ could induce cellular transformation when overexpressed in non-tumorigenic cells. First, the ability of ChoKβ-transfected cells to promote anchorage independent cell growth was determined using the cell line HEK293T. As previously reported, ChoKα1 induced a significant increase in the number of soft agar colonies [15]. By contrast, under similar conditions, ChoKβ overexpression had no significant effect on the number nor the size of the colonies when compared to those generated by control, empty vector transfected HEK293T cells (Fig. 3). These results were confirmed using another non-tumorigenic cell line from a different species such as MDCK, obtaining similar results despite of the lower level of overexpression of both ChoK isoforms compared to the HEK293T cells. The differential level of expression obtained was due to the rather different efficiency in transfection for each cell lines (data not shown).

Figure 3
Anchorage independent cell growth of ChoKα1- and β1-overexpressing cells.

The ability of ChoKβ to induce tumour growth was also investigated. Both ChoKα1- and ChoKβ-transfected HEK293T or MDCK cells were subcutaneously inoculated into athymic mice. As shown in Fig. 4, the overexpression of ChoKα1 was sufficient to induce tumour growth in immunosuppressed mice in the both cell systems analyzed. By contrast, cells overexpressing ChoKβ were not able to induce tumor growth under similar conditions. As indicated above, comparison in tumor growth rates between both cell lines is related to the diverse efficiency of transfection, much higher in HEK293T (aproxm. 80–90%) than MDCK (aproxm. 15–20%). These results are in keeping with those obtained in the soft-agar experiments, and strongly indicate that overexpression of ChoKβ is not sufficient to induce tumor growth under conditions where ChoKα1 does.

Figure 4
Overexpression of ChoKβ1 is not sufficient to induce tumor growth in athymic nude mice.

ChoKβ isoform shows preferential EtnK activity in vivo

We next investigated if there was any difference in the enzymatic activity of both ChoK isoforms under in vivo conditions that could explain their differential biological activity. Thus, the activity of ChoKα1 and ChoKβ as ChoK and/or EtnK in a whole-cell system was tested. Intracellular lipids of human HEK293T overexpressing ChoKα1, ChoKβ or transfected with an empty vector, were extracted an analyzed. Both, the insoluble lipid fraction containing the hydrophobic lipids and total protein content were used as loading control obtaining similar results. As shown in Figure 5A, the intracellular phosphoethanolamine levels were increased to a similar extent in ChoKα1− or ChoKβ-transfected cells. However, the intracellular phosphocholine levels of ChoKβ-transfected cells were not significantly different to that of control cells, while ChoKα1-transfected cells showed an increased intracellular PCho levels (Figure 5B). Similar results were obtained using epithelial cells of different origins: human breast adenocarcinoma cells SK-Br-3 (Fig. 5C, D) or the human Non Small Cell Lung Cancer (NSCLC) cell line H1299 (Fig. 5E, F). In addition, in all cell lines analyzed, protein expression was also determined by Western Blot analysis (Fig. 5G).

Figure 5
Intracellular phosphocholine and phospoethanolamine levels after ChoKα1 or ChoKβ1 transfection in human cells.

Thus, the differential enzymatic activity of ChoKα1 and ChoKβ found in HEK293T is not cell line specific. These results indicate that ChoKα1 but not ChoKβ, is able to induce increased intracellular levels of PCho under in vivo conditions. However, under the same conditions both enzymes are able to generate phophorylethanolamine. Thus, even though ChoKβ displays both ChoK and EtnK activity under in vitro conditions, it shows preferential EtnK activity in vivo.

Increased levels of ChoKα mRNA but not ChoKβ in tumor-derived cell lines

In order to further investigate the relevance of each ChoK isoenzyme in tumorogenesis, we determined the levels of both ChoKα and ChoKβ mRNA in a panel of human tumour-derived cell lines by quantitative PCR technology. A panel of breast and lung cancer cell lines were compared with the primary, senescent, non-tumoral cell line HMEC (Human Mammary Epithelial Cells) or the immortalized, non-tumorogenic MCF10A cells as control breast cell lines, and primary Bronchial Epithelial Cells (BEC) as control lung cell line. All tumoral cell lines tested significantly overexpress ChoKα mRNA compared with the normal cell lines, whereas no changes were found for ChoKβ mRNA levels (Fig. 6). These results indicate that ChoKβ is not specifically upregulated in breast or lung cancer cells, suggesting that high levels of ChoKβ are not required for the promotion of cancer.

Figure 6
Comparative expression of ChoKα1 and ChoKβ1 mRNA in a panel of cancer cell lines.

MN58b is a specific inhibitor of ChoKα isoform

The implication of ChoKα in human carcinogenesis has been used for the design of specific inhibitors of this enzyme as a novel anticancer strategy [2], [14], [37]. MN58b is the leading compound to support this novel strategy since it has shown a potent antitumoral activity under in vivo conditions versus human colon, lung, breast and bladder tumor models [15], [37].

The primary structure of mammalian ChoKβ displays an overall 60% homology with that of ChoKα1 [1]. The higher degree of homology lies within the choline/ethanolamine kinase domain. This homology could make it susceptible to a similar inhibition for both ChoKα1 and ChoKβ with the same inhibitors. Thus, we have investigated the specificity of MN58b towards these two ChoK isoenzymes in order to verify if its antitumoral effect is specifically related to the inhibition of the alpha isoform, that is the one implicated in tumor progression, or the drug similarly affects both isoforms. Using the human ChoKα1 and ChoKβ recombinant proteins, we performed an in vitro ChoK activity inhibition assay using increasing MN58b concentrations, determining the IC50 for each enzyme. As expected, despite the high similarity displayed between ChoK isoforms, MN58b showed a much higher specificity against ChoKα1 (IC50 = 5 µM) than against ChoKβ (IC50 = 107.5 µM). Thus, MN58b is 21.5 times more potent against ChoKα1 than ChoKβ isoform.

Discussion

The family of human choline/ethanolamine kinases comprises two genes, CHKA and CHKB that codify for three enzymes, ChoKα1 (52 kDa), ChoKα2 (50 kDa) and ChoKβ1 (45 kDa). ChoKα1 and ChoKα2 are almost identical, except for a stretch of 18 extra amino acids in ChoKα1, as they result from differential splicing from the same gene, CHKA. While the implication of ChoKα1 in the regulation of cell growth and cancer has been extensively demonstrated [13], [15], [27], [28], [37], [38], [44], preliminary evidence suggest that ChoKβ may not be involved in carcinogenesis since it is not overexpressed in breast cancer cell lines [21] nor in the TRAMP mouse prostate cancer model [31].

A distinct human gene family has been described that codifies for EtnK activity [45], suggesting that EtnK1 is the main enzyme involved in PE homeostasis. The ChoK/EtnK domain confers to ChoKα and ChoKβ the ability to function as both ChoK and EtnK activity under cell-free conditions [1], [3][5], but it is still unknown if these previously characterized enzymes showed any selectivity to each branch of the Kennedy pathway in the de novo synthesis of PC or PE. It has been recently described the different specificity towards Cho and Etn of the two isoforms of Cho/EtnK of Tripanosoma brucei. Whereas TbCho/Etn1 displays only EtnK activity, TbCho/Etn2 displays both ChoK and EtnK activities in vitro [46]. These results are in keeping with those described for murine EtnK1 that is Etn specific and EtnK2 that displays a dual ChoK/EtnK function [45], [47]. On the other hand, whereas murine Pcyt1α and Pcyt1β are involved in PC biosynthesis, Pcyt2 is focused to PE only [48].

However, it is not yet fully understood which ChoK isoform, if any, contributes in vivo in each pathway to maintain the normal homeostasis of both PC and PE in biological membranes. The results shown here confirm that both enzymes have the ability to phosphorylate choline and ethanolamine under cell-free conditions, either as recombinant proteins produced in E. coli, or in cell extracts from mammalian cells. However, we found that under whole cell conditions ChoKα1 has the ability to function as both ChoK and EtnK, but ChoKβ only affects the production of PEtn. These findings of different roles for α and β isoforms are in keeping with the information from the recently generated Knock Out (KO) mice for ChoKα and ChoKβ genes [49], [50]. Thus, ChoKβ KO mice (rmd mice) are viable, but develop a rostrocaudal muscular dystrophy, while normal PC lipid levels are found in most tissues analyzed except in hindlimb skeletal muscle [49]. Therefore, ChoKα is sufficient to maintain normal PC levels in most tissues. By contrast, the lack of ChoKα results in embryonic lethality, and ChoKα+/− heterozygous mice display an accumulation of Cho and a reduction in PCho in liver and testis, suggesting that there is no ChoKβ compensation for PC biosynthesis in vivo. These results suggest different roles in vivo for both ChoKα and ChoKβ isoforms. Furthermore, the attenuated levels in PE found in ChoKα+/− heterozygous mice suggest the involvement of ChoKα not only in the biosynthesis of PC but also in the PE pathway. This is also consistent with the fact that in ChoKβ KO mice, PE levels are unaffected, indicating that PE homeostasis is fully maintained with the EtnK1 and ChoKα proteins intact.

The group of Ishidate has provided valuable information about the in vitro activity of ChoK from different mouse tissues, and they have postulated that the most active form for choline kinase activity is the α/α homodimer followed by α/β heterodimers, being the β/β homodimer the least active form [8]. The in vivo results shown here are partially in keeping with this hypothesis. The in vivo activity of ChoKβ is focused in PE biosynthesis and displays higher Km for choline than ChoKα, this could be the reason why β/β dimers show low ChoK activity. When ChoKβ was overexpressed we observed an increase in the intracellular levels of PEtn but not of PCho. However no differences were found between both isoforms for the generation of PEtn, since both display similar EtnK activity.

PCho has been proposed to promote mitogenesis in mammalian cells [12]. In keeping with this, magnetic resonance spectroscopy techniques have revealed higher levels of phosphomonoesthers in tumoral samples when compared to their normal counterparts [19][24]. Moreover, overexpression of ChoKα1 is oncogenic [15], and enhanced ChoKα activity is a frequent feature in tumoral samples compared to normal tissues [27], [28]. Taken together all these results strongly indicate that ChoKα1 activity and PCho levels have a strong implication in cancer. Furthermore, overexpression of ChoKα1 results in an increase in EtnK activity and PEtn levels. However the latter effect by itself is not sufficient to induce cell transformation, since overexpression of ChoKβ does not induce enhanced colony formation in soft-agar or tumor growth in nude mice. These results are consistent with the hypothesis that it is the production of PCho what is linked to cell proliferation and transformation mediated by ChoK, and that the production of PEtn may not be sufficient or relevant in this process.

The above results suggest that the two ChoK isoforms investigated, besides their similarity in their primary sequences, are implicated in different metabolic pathways. Thus while ChoKα1 impinges into both PC and PE synthesis, ChoKβ affects only PE synthesis. Furthermore, the transformation capacity seems to be exclusive to the ChoKα isoform. However, since in the human HEK293T, Sk-Br-3 and H1299 cell lines, ChoKα1 overexpression produces elevated levels of both PCho and PEtn, while similar ChoKβ overexpression results only in higher levels of PEtn but normal levels of PCho, we can not rule out the possibility that cell transformation requires both ChoK and EtnK activities.

Consistent with the idea that links oncogenic activity to the function of ChoKα, but not ChoKβ, the antiproliferative and antitumoral activity of MN58b was only associated to the activity of ChoKα. Furthermore, as previously reported, the in vivo treatment with MN58b results in a specific decrease of PCho levels in the tumours but no significant effect on the levels of PEtn [51]. Previous results from our group have demonstrated that MN58b also inhibits choline transport [38]. However this effect has a little influence in the antiproliferative and antitumoral activity of the drug since HC-3, a much more potent inhibitor of choline transporters, is far less potent as an antiproliferative agent than MN58b [2]. Furthermore, MN58b has a differential effect on either normal or tumor cells, a strong demonstration of a differential activity due to ChoK inhibition [38][40]. These results are also in keeping with the observation that ChoKα but not ChoKβ is a downstream target of oncogenic molecules such as Ras and RhoA. Thus, while Ras activates ChoKα through Ral-GDS and PI3K [29], and RhoA activates ChoKα through ROCK [15], none of these oncogenic GTPases affect ChoKβ activity under similar conditions. Again, these results indicate that although both ChoK enzymes are able to phosphorylate both choline and ethanolamine under cell-free systems conditions, they display different affinities for these substrates, and in whole-cell assays conditions they are governed by distinct regulatory pathways.

Finally, the involvement of ChoKβ in breast and lung cancer has been studied, ChoKα and β mRNA levels were determined by Q-PCR. All tumour-derived cell lines assayed significantly overexpress ChoKα mRNA, while no changes were found in the expression of ChoKβ. Similar results have been recently reported, using semi-quantitative PCR in breast cancer cell lines [21]. In addition, it has been recently described that elevated mRNA levels of ChoKα is a poor prognostic factor in lung cancer [30]. These results suggest that ChoKα but not ChoKβ is playing a crucial role in human carcinogenesis.

The results shown here suggest that ChoKβ and its produced metabolites are not implicated in human cell transformation. Therefore, all the efforts aimed at dilucidating the involvement of ChoK activity in the diagnosis, prognosis and treatment of cancer have to be focused in the ChoKα isoform. In keeping with this, recently the use of specific monoclonal anti-ChoKα antibodies has been proposed as a diagnostic tool in human cancer [52]. Furthermore, the newly designed antitumoral agents are expected to be more specific and hence less toxic than the actual drugs used in conventional chemotherapy. Due to the high structural homology displayed by both choline kinase proteins, the search for new anticancer agents based on their ability to interfere with ChoK activity, must exhibit stronger antiproliferative activity based on their specificity towards the ChoKα isoform.

The lack of specific inhibition of ChoKβ by these newly designed compounds represents a new feature to take into account for the chemical improvement of ChoKα inhibitors with potential antitumoral activity. Furthermore, non-specific drugs affecting ChoKβ may result in a muscular disease produced by the lack of cell membrane lipid reparation in muscle tissue.

In addition, it has been recently demonstrated using a genetic approach that the specific inhibition of ChoKα by shRNA displays antiproliferative and antitumoral activity The high specificity of this technology provides definitive evidence of an antitumoral strategy based on ChoKα inhibition, supporting previous results with the pharmacological inhibitors. [53][55]

Thus, despite the high homology and similar activity displayed under cell-free conditions, ChoKα1 and ChoKβ isoforms show a different substrate ability and behave very differently under in vivo conditions, suggesting that in human cells, ChoKβ behaves as an EtnK and its overexpression is not able to induce higher intracellular levels of PCho. As a consequence, ChoKβ has no effect on cell proliferation and does not contribute to oncogenic transformation. Finally, ChoKα but not ChoKβ, should be used as the molecular target for the design of anticancer drugs aiming at interfering with choline kinase acitivity.

Materials and Methods

Ethics statement

All animals were handled in strict accordance with good animal practice as defined by the Guidelines of the Spanish Government (RD 223/1988, March 14th and RD 1201/2005 October 10th). The animal work has been conducted under the permission and supervision of the Consejo Superior de Investigaciones Cientificas (CSIC) Ethic Committee as approved in the context of the appropriate Research Project.

Cell cultures and transfections

Cells were maintained under standard culture conditions of humidity (95%), temperature (37°C) and CO2 (5%). Human Embryonic Kidney (HEK293T), human breast adenocarcinoma (SK-Br-3) and Canine Kidney Madin-Darby (MDCK) cells were maintained in DMEM supplemented with 10% FBS, human non-small cell lung cancer cells H1299 were maintained in RPMI with 10% FBS. HEK293T transfections were performed using calcium phosphate as previously described [56]. MDCK, SK-Br-3 and H1299 cells were transfected using lipofectamine reagent (Invitrogen, CA) following manufacturers recommendations. Eukaryotic expression vectors encoding for human ChoKα1 and β1 isoforms were pCDNA3b (Invitrogen, CA) and pLPneo (BD Biosciences Clontech, CA) respectively, both empty vectors were used as controls but only pCDNA3b is usually represented (data not shown). Constitutively activated expression pCDNA3b derivative vectors encoding for RhoA (QL), Rac1 (QL) and Cdc42 (QL) have been previously described [57]. Expression vector encoding to the constitutive active form of H-Ras (V12) have been previously described [29].

Choline kinase in vitro activity assays

Eukaryotic cell extracts activity assays were carried out as previously described [14]. Cell extracts were incubated for 30 min at 37°C in a buffer containing 100 mM Tris pH 8, 10 mM MgCl2 and 10 mM ATP and 200 µM (55 mCi/nmol, 2 µCi/ml) of [methyl-14C] choline chloride (Amersham Biosciences, UK) for ChoK assay or 2-[14C]-ethan-1-ol-2-amine hydrochloride for EtnK assay (Amersham Biosciences).

For Michaelis-Menten kinetics assay, extracts of E. coli expressing human ChoKα1 or ChoKβ1 were used. A time course reaction was performed for each substrate, the reaction was stopped each 2 minutes and a logarithmic scale was represented to obtain the Km. Specific ChoK inhibitor MN58b was kindly provided by TCD Pharma SL (Madrid, Spain).

Analysis of phosphocholine and phosphoethanolamine production in whole cells

HEK293T, SK-Br-3 and H1299 cells were transfected as described above. After transfection, cells were labelled to equilibrium adding 1 µCi/ml [methyl-14C] choline chloride or 1 µCi/ml 2-[14C]-ethan-1-ol-2-amine hydrochloride to the culture media for 24 h. Samples were resolved and quantified as previously described [37]. Briefly, cells were rinsed with PBS and fixed with 16% ice-cold trichloroacetic acid (TCA). TCA-soluble material containing choline and phosphocholine was washed three times with four volumes of diethyleter, dryed under vacuum and resuspended in water. Samples were resolved by Thin Layer Chromatography (TLC) on 60Å Silica gel plates (Whatman, NJ), using as liquid phase 0,9% NaCl: methanol: ammonium hydroxide (50[ratio]70[ratio]5; v/v/v). Radioactivity was automatically quantified by an electronic radiography system (Instantimager, CT). TCA insoluble material containing hydrophobic lipids was used as a loading control. The insoluble fraction was dissolved in 0,25N sodium hydroxide and total lipids were analyzed by scintillation counting.

Anti-choline kinase β1 serum

Human ChoKβ1 gene was cloned into a prokaryotic expression vector (pGEX-4T3) (GE healthcare, UK) and expressed in DH5α Escherichia coli. Recombinant ChoKβ1 was then purified by the GST system (Amersham Bioscience) following manufacturer's recommendations. Purified ChoKβ1 was mixed (1[ratio]1; v/v) with Freund's complete Adjuvant (Sigma-Aldrich, MO) and then injected i.m. into white rabbits (80 µg/rabbit). Booster injections were given every 2 weeks (60 µg/rabbit) and the sample resuspended with Freund's incomplete Adjuvant (Sigma-Aldrich) (1[ratio]1; v/v).

Analysis of protein expression by Western blot

Equal amounts of cell lysates were resolved by electrophoresis in a 10% SDS-PAGE. ChoKα expression levels were detected using monoclonal antibody AD3 as previously described [52]. ChoKβ1 was detected using the polyclonal antiserum described above as primary antibody at a standard dilution of 1/5000. GTPases antibodies: RhoA (Santa Cruz Biotechnology, Germany), Rac1 (Upstate, NY), pan-Ras (Santa Cruz Biotechnology), Cdc42 (BD Biosciences, transduction labs) and GAPDH antibody (Chemicon International, CA) were used following manufacturers recommendations. HRP-conjugated secondary antibodies were from Santa Cruz Biotechnology. The specific binding was detected using the chemioluminiscence detection kit ECL (Amersham Bioscience) following the manufacturer indications.

Soft agar anchorage-independent growth and in vivo tumorigenic assays

Anchorage-independent growth assays were performed at 5–6 weeks of incubation in HEK293T and 6–10 weeks in MDCK, as previously described [15], plating 105 cells per 60-mm dish. Crystal violet staining was performed to enhance colony contrast. The number of colonies was automatically quantified by computer based image software (Image J). For the in vivo assays, cells were injected (106 cells per mouse flank) s.c. in nu/nu athymic mice. Mice were kept under standard laboratory conditions according to the guidelines of Spanish Government.

Quantitative PCR

ChoKα1 or β1 mRNA levels were quantified by real-time reverse transcriptase PCR. The RNA was extracted from the cell lines using QIAshredder following the RNeasy Mini kit (Qiagen, Inc.) according to the manufacturer's instructions. The amount of 0.9 µg of total RNA, in a final concentration of 10 ng/µl per reaction, was retro transcribed by High-Capacity cDNA Archive Kit (Applied Biosystems) to the cDNA preparation. The reverse transcription conditions were 25°C for 10 min and 37°C for 2 h. Then, each cDNA sample was analyzed in triplicate using the ABI PRISM 7700 Sequence Detector (PE Applied Biosystems). Real-time PCR was carried out using Taqman Universal PCR Master Mix (Applied Biosystems), containing ROX to normalize emissions. Primers used for amplification of ChoKα, ChoKβ and 18S ribosomal RNA were purchased from Applied Biosystems as Taqman Gene Expression Assays (ChoKα1 ID: Hs00608045_m1, ChoKβ1 ID: Hs01925200_s1 and 18S ribosomal RNA ID: Hs99999901_s1). For thermal cycling, the following conditions were applied: 10 min at 95°C and 40 cycles of 15 sec at 95°C and 1 min at 60°C. The data are presented as Log10 RQ (Relative Quantity).

Statistical analysis

Mean comparisons of ChoK activity or in-cell PCho increase between different groups were performed. Continuous variables with normal distribution were compared by T-test and non-normal distribution variables were compared by means of the Kruskal Wallis and Mann-Whitney U tests. Statistical significance was defined as p≤0.05. The statistical analyses were performed using SPSS software, version 13.0 (Inc, Chicago, Illinois). The method used to analyze data from real-time PCR experiments was 2−ΔΔCt method [58], comparing the relative gene expression between normal and tumoral cell lines normalized to 18S ribosomal RNA as endogenous reference gene.

Acknowledgments

We thank Dr. Leonardo Brizuela and Dr. Jaehong Park for kindly providing the human ChoKβ gene and Elena Bogonez ( Centro de Investigaciones Biologicas, Madrid) for her technical advices in Km determination. DGO is a fellow from Comunidad de Madrid/FPI 2004.

Footnotes

Competing Interests: The authors have declared that no competing interests exist.

Funding: This work has been supported by grants to JCL from Comunidad de Madrid (GR-SAL-0821-2004), Ministerio de Ciencia e Innovación (SAF2008-03750, RD06/0020/0016), Fundación Mutua Madrileña, and by a grant to ARM from Fundación Mutua Madrileña. DGO was a fellow from Comunidad de Madrid. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Aoyama C, Liao H, Ishidate K. Structure and function of choline kinase isoforms in mammalian cells. Prog Lipid Res. 2004;43:266–281. [PubMed]
2. Lacal JC. Choline kinase: a novel target for antitumor drugs. IDrugs. 2001;4:419–426. [PubMed]
3. Uchida T, Yamashita S. Molecular cloning, characterization, and expression in Escherichia coli of a cDNA encoding mammalian choline kinase. J Biol Chem. 1992;267:10156–10162. [PubMed]
4. Porter TJ, Kent C. Purification and characterization of choline/ethanolamine kinase from rat liver. J Biol Chem. 1990;265:414–422. [PubMed]
5. Aoyama C, Nakashima K, Ishidate K. Molecular cloning of mouse choline kinase and choline/ethanolamine kinase: their sequence comparison to the respective rat homologs. Biochim Biophys Acta. 1998;1393:179–185. [PubMed]
6. Malito E, Sekulic N, Too WC, Konrad M, Lavie A. Elucidation of human choline kinase crystal structures in complex with the products ADP or phosphocholine. J Mol Biol. 2006;364:136–151. [PMC free article] [PubMed]
7. Zhou J, Liu CY, Back SH, Clark RL, Peisach D, et al. The crystal structure of human IRE1 luminal domain reveals a conserved dimerization interface required for activation of the unfolded protein response. Proc Natl Acad Sci U S A. 2006;103:14343–14348. [PMC free article] [PubMed]
8. Aoyama C, Ohtani A, Ishidate K. Expression and characterization of the active molecular forms of choline/ethanolamine kinase-alpha and -beta in mouse tissues, including carbon tetrachloride-induced liver. Biochem J. 2002;363:777–784. [PMC free article] [PubMed]
9. Carnero A, Cuadrado A, del Peso L, Lacal JC. Activation of type D phospholipase by serum stimulation and ras-induced transformation in NIH3T3 cells. Oncogene. 1994;9:1387–1395. [PubMed]
10. Carnero A, Lacal JC. Phospholipase-induced maturation of Xenopus laevis oocytes: mitogenic activity of generated metabolites. J Cell Biochem. 1993;52:440–448. [PubMed]
11. Rodriguez-Gonzalez A, Ramirez de Molina A, Benitez-Rajal J, Lacal JC. Phospholipase D and choline kinase: their role in cancer development and their potential as drug targets. Prog Cell Cycle Res. 2003;5:191–201. [PubMed]
12. Cuadrado A, Carnero A, Dolfi F, Jimenez B, Lacal JC. Phosphorylcholine: a novel second messenger essential for mitogenic activity of growth factors. Oncogene. 1993;8:2959–2968. [PubMed]
13. Ramirez de Molina A, Banez-Coronel M, Gutierrez R, Rodriguez-Gonzalez A, Olmeda D, et al. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res. 2004;64:6732–6739. [PubMed]
14. Hernandez-Alcoceba R, Saniger L, Campos J, Nunez MC, Khaless F, et al. Choline kinase inhibitors as a novel approach for antiproliferative drug design. Oncogene. 1997;15:2289–2301. [PubMed]
15. Ramirez de Molina A, Gallego-Ortega D, Sarmentero J, Banez-Coronel M, Martin-Cantalejo Y, et al. Choline kinase is a novel oncogene that potentiates RhoA-induced carcinogenesis. Cancer Res. 2005;65:5647–5653. [PubMed]
16. Lacal JC, Moscat J, Aaronson SA. Novel source of 1,2-diacylglycerol elevated in cells transformed by Ha-ras oncogene. Nature. 1987;330:269–272. [PubMed]
17. Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nat Rev Cancer. 2004;4:551–561. [PubMed]
18. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed. 1992;5:303–324. [PubMed]
19. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res. 1999;59:80–84. [PubMed]
20. Cheng LL, Burns MA, Taylor JL, He W, Halpern EF, et al. Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res. 2005;65:3030–3034. [PubMed]
21. Eliyahu G, Kreizman T, Degani H. Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int J Cancer. 2007;120:1721–1730. [PubMed]
22. Glunde K, Serkova NJ. Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. Pharmacogenomics. 2006;7:1109–1123. [PubMed]
23. Kurhanewicz J, Vigneron DB, Nelson SJ. Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. Neoplasia. 2000;2:166–189. [PMC free article] [PubMed]
24. Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, et al. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res. 2005;65:9369–9376. [PubMed]
25. Spadaro F, Ramoni C, Mezzanzanica D, Miotti S, Alberti P, et al. Phosphatidylcholine-specific phospholipase C activation in epithelial ovarian cancer cells. Cancer Res. 2008;68:6541–6549. [PubMed]
26. Bell JD, Bhakoo KK. Metabolic changes underlying 31P MR spectral alterations in human hepatic tumours. NMR Biomed. 1998;11:354–359. [PubMed]
27. Ramirez de Molina A, Gutierrez R, Ramos MA, Silva JM, Silva J, et al. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene. 2002;21:4317–4322. [PubMed]
28. Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, Martinez-Pineiro L, Sanchez J, et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun. 2002;296:580–583. [PubMed]
29. Ramirez de Molina A, Penalva V, Lucas L, Lacal JC. Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K. Oncogene. 2002;21:937–946. [PubMed]
30. Ramirez de Molina A, Sarmentero-Estrada J, Belda-Iniesta C, Taron M, Ramirez de Molina V, et al. Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol. 2007;8:889–897. [PubMed]
31. Teichert F, Verschoyle RD, Greaves P, Edwards RE, Teahan O, et al. Metabolic profiling of transgenic adenocarcinoma of mouse prostate (TRAMP) Tissue by (1)H-NMR analysis: evidence for unusual phospholipid metabolism. Prostate. 2008;68:1035–1047. [PubMed]
32. Gomez del Pulgar T, Benitah SA, Valeron PF, Espina C, Lacal JC. Rho GTPase expression in tumourigenesis: evidence for a significant link. Bioessays. 2005;27:602–613. [PubMed]
33. Boettner B, Van Aelst L. The role of Rho GTPases in disease development. Gene. 2002;286:155–174. [PubMed]
34. Aznar S, Fernandez-Valeron P, Espina C, Lacal JC. Rho GTPases: potential candidates for anticancer therapy. Cancer Lett. 2004;206:181–191. [PubMed]
35. Aznar S, Lacal JC. Searching new targets for anticancer drug design: the families of Ras and Rho GTPases and their effectors. Prog Nucleic Acid Res Mol Biol. 2001;67:193–234. [PubMed]
36. Ramirez de Molina A, Rodriguez-Gonzalez A, Lacal JC. From Ras signalling to ChoK inhibitors: a further advance in anticancer drug design. Cancer Lett. 2004;206:137–148. [PubMed]
37. Hernandez-Alcoceba R, Fernandez F, Lacal JC. In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery. Cancer Res. 1999;59:3112–3118. [PubMed]
38. Rodriguez-Gonzalez A, de Molina AR, Fernandez F, Ramos MA, Nunez Mdel C, et al. Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells. Oncogene. 2003;22:8803–8812. [PubMed]
39. Rodriguez-Gonzalez A, Ramirez de Molina A, Banez-Coronel M, Megias D, Lacal JC. Inhibition of choline kinase renders a highly selective cytotoxic effect in tumour cells through a mitochondrial independent mechanism. Int J Oncol. 2005;26:999–1008. [PubMed]
40. Rodriguez-Gonzalez A, Ramirez de Molina A, Fernandez F, Lacal JC. Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action. Oncogene. 2004;23:8247–8259. [PubMed]
41. Ishidate K, Furusawa K, Nakazawa Y. Complete co-purification of choline kinase and ethanolamine kinase from rat kidney and immunological evidence for both kinase activities residing on the same enzyme protein(s) in rat tissues. Biochim Biophys Acta. 1985;836:119–124. [PubMed]
42. Ishidate K, Nakagomi K, Nakazawa Y. Complete purification of choline kinase from rat kidney and preparation of rabbit antibody against rat kidney choline kinase. J Biol Chem. 1984;259:14706–14710. [PubMed]
43. Uchida T, Yamashita S. Purification and properties of choline kinase from rat brain. Biochim Biophys Acta. 1990;1043:281–288. [PubMed]
44. Ramirez de Molina A, Rodriguez-Gonzalez A, Penalva V, Lucas L, Lacal JC. Inhibition of ChoK is an efficient antitumor strategy for Harvey-, Kirsten-, and N-ras-transformed cells. Biochem Biophys Res Commun. 2001;285:873–879. [PubMed]
45. Lykidis A, Wang J, Karim MA, Jackowski S. Overexpression of a mammalian ethanolamine-specific kinase accelerates the CDP-ethanolamine pathway. J Biol Chem. 2001;276:2174–2179. [PubMed]
46. Gibellini F, Hunter WN, Smith TK. Biochemical characterisation of the initial steps of the kennedy pathway in Trypanosoma brucei - the ethanolamine and choline kinases. Biochem J 2008 [PMC free article] [PubMed]
47. Weinhold PA, Rethy VB. The separation, purification, and characterization of ethanolamine kinase and choline kinase from rat liver. Biochemistry. 1974;13:5135–5141. [PubMed]
48. Tijburg LB, Geelen MJ, van Golde LM. Regulation of the biosynthesis of triacylglycerol, phosphatidylcholine and phosphatidylethanolamine in the liver. Biochim Biophys Acta. 1989;1004:1–19. [PubMed]
49. Sher RB, Aoyama C, Huebsch KA, Ji S, Kerner J, et al. A rostrocaudal muscular dystrophy caused by a defect in choline kinase beta, the first enzyme in phosphatidylcholine biosynthesis. J Biol Chem. 2006;281:4938–4948. [PubMed]
50. Wu G, Aoyama C, Young SG, Vance DE. Early embryonic lethality caused by disruption of the gene for choline kinase alpha, the first enzyme in phosphatidylcholine biosynthesis. J Biol Chem 2007 [PMC free article] [PubMed]
51. Al-Saffar NM, Troy H, Ramirez de Molina A, Jackson LE, Madhu B, et al. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Res. 2006;66:427–434. [PubMed]
52. Gallego-Ortega D, Ramirez De Molina A, Gutierrez R, Ramos MA, Sarmentero J, et al. Generation and characterization of monoclonal antibodies against choline kinase alpha and their potential use as diagnostic tools in cancer. Int J Oncol. 2006;29:335–340. [PubMed]
53. Banez-Coronel M, de Molina AR, Rodriguez-Gonzalez A, Sarmentero J, Ramos MA, et al. Choline kinase alpha depletion selectively kills tumoral cells. Curr Cancer Drug Targets. 2008;8:709–719. [PubMed]
54. Glunde K, Raman V, Mori N, Bhujwalla ZM. RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res. 2005;65:11034–11043. [PubMed]
55. Krishnamachary B, Glunde K, Wildes F, Mori N, Takagi T, et al. Noninvasive detection of lentiviral-mediated choline kinase targeting in a human breast cancer xenograft. Cancer Res. 2009;69:3464–3471. [PMC free article] [PubMed]
56. Montaner S, Perona R, Saniger L, Lacal JC. Activation of serum response factor by RhoA is mediated by the nuclear factor-kappaB and C/EBP transcription factors. J Biol Chem. 1999;274:8506–8515. [PubMed]
57. Montaner S, Perona R, Saniger L, Lacal JC. Multiple signalling pathways lead to the activation of the nuclear factor kappaB by the Rho family of GTPases. J Biol Chem. 1998;273:12779–12785. [PubMed]
58. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–408. [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Compound
    Compound
    PubChem Compound links
  • Gene
    Gene
    Gene links
  • GEO Profiles
    GEO Profiles
    Related GEO records
  • HomoloGene
    HomoloGene
    HomoloGene links
  • MedGen
    MedGen
    Related information in MedGen
  • Pathways + GO
    Pathways + GO
    Pathways, annotations and biological systems (BioSystems) that cite the current article.
  • Protein
    Protein
    Published protein sequences
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links
  • Taxonomy
    Taxonomy
    Related taxonomy entry
  • Taxonomy Tree
    Taxonomy Tree

Recent Activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...